Next-generation sequencing assay in salivary gland cytology: A pilot study
| Autor: | Kana Tsuda, Yoshihide Okumura, Ayako Masaki, Daisuke Kawakita, Hiroshi Inagaki, Kaori Ueda, Yuma Sakamoto, Satsuki Nakano, Shuhei Yamamoto, Keiichiro Fujii, Takayuki Murase |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Pilot Projects Malignancy Sensitivity and Specificity DNA sequencing Salivary Glands Pathology and Forensic Medicine Ancillary test Benign tumor 03 medical and health sciences 0302 clinical medicine Cytology Medicine Retrospective Studies Suspicious for Malignancy Salivary gland business.industry High-Throughput Nucleotide Sequencing 030206 dentistry medicine.disease DNA extraction medicine.anatomical_structure Otorhinolaryngology 030220 oncology & carcinogenesis Periodontics Oral Surgery business |
| Zdroj: | Journal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral PathologyREFERENCES. 49(10) |
| ISSN: | 1600-0714 |
| Popis: | Background Preoperative diagnosis of salivary gland tumors (SGTs) by fine-needle aspiration (FNA) cytology is challenging. Next-generation sequencing (NGS)-based assays for somatic mutations have a great advantage in that a large number of genes can be analyzed simultaneously. Although NGS may have an enormous diagnostic potential in cytology, to our knowledge, the significance of NGS in SGT cytology remains to be clarified. Methods In this pilot study, we retrospectively examined 32 frozen SGT samples obtained at surgery (14 malignant and 18 benign). After the stored frozen tumor tissues were thawed, aspirate samples were obtained using 22-gauge needles and subjected to smear tumor samples and to DNA extraction for an NGS assay employing the Illumina AmpliSeq Cancer Hotspot Panel v2. The results were correlated to preoperative cytological diagnosis. Results The preoperative diagnoses obtained by FNA cytology included 23 negative lesions (no malignancy in 6 and benign tumor in 17) and nine positive lesions (suspicious for malignancy in 4 and malignancy in five), providing a sensitivity and a specificity of 9/14 (64%) and 18/18 (100%), respectively. The NGS assay detected somatic mutations in 10/14 malignant and 1/18 benign SGT cases, providing a sensitivity and a specificity of 71% and 94%, respectively. Conclusion The NGS assay may be helpful for detecting the malignant potential in SGT cases and can be used as an ancillary test for SGT cytology. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text